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Abstract Fatigue is a common, disabling, and difficult-to-
manage problem in rheumatic diseases. Prevalence estimates
of fatigue within rheumatic diseases vary considerably. Data
on the prevalence of severe fatigue across multiple rheumatic
diseases using a similar instrument is missing. Our aim was to
provide an overview of the prevalence of severe fatigue across
a broad range of rheumatic diseases and to examine its asso-
ciation with clinical and demographic variables. Online ques-
tionnaires were filled out by an international sample of 6120
patients (88 % female, mean age 47) encompassing 30 differ-
ent rheumatic diseases. Fatigue was measured with the
RAND(SF)-36 Vitality scale. A score of ≤35 was taken as
representing severe fatigue (90 % sensitivity and 81 % spec-
ificity for chronic fatigue syndrome). Severe fatigue was pres-
ent in 41 to 57 % of patients with a single inflammatory rheu-
matic disease such as rheumatoid arthritis, systemic lupus er-
ythematosus, ankylosing spondylitis, Sjögren’s syndrome,
psoriatic arthritis, and scleroderma. Severe fatigue was least
prevalent in patients with osteoarthritis (35 %) and most prev-
alent in patients with fibromyalgia (82 %). In logistic regres-
sion analysis, severe fatigue was associated with having fibro-
myalgia, havingmultiple rheumatic diseases without fibromy-
algia, younger age, lower education, and language (French:
highest prevalence; Dutch: lowest prevalence). In conclusion,
one out of every two patients with a rheumatic disease is
severely fatigued. As severe fatigue is detrimental to the pa-
tient, the near environment, and society at large, unraveling
the underlying mechanisms of fatigue and developing optimal
treatment should be top priorities in rheumatologic research
and practice.
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Introduction
Fatigue is a common problem in patients with a rheumatic
disease. It can be as disabling as pain, is difficult to manage,
and has a substantial impact on quality of life [1–10]. In re-
search and clinical practice, multiple instruments have been
used to assess fatigue, representing disease-specific versus
generic as well as unidimensional versus multidimensional
definitions of fatigue [4, 11, 12]. As a consequence, it is dif-
ficult to determine how widespread severe fatigue really is
among patients with rheumatic diseases. Indeed, prevalence
estimates of fatigue vary considerably within rheumatic dis-
eases [4], and the evaluation of the prevalence of severe fa-
tigue with a uniform measure across different rheumatic dis-
eases has been limited to comparing just a few rheumatic
diseases at a time [3, 13]. In this study, we chose a common
generic (not disease-specific), unidimensional specification of
fatigue to be able to estimate the prevalence of a severe level
of fatigue across multiple rheumatic diseases.
Fatigue has been indicated to be more prevalent in patients
with more than one rheumatic disease [3], and there are some
indications for a higher prevalence in women [2, 5] and in
people with a lower social economic status [14]. So far, no
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significant associations have been reported between fatigue
and other demographics such as age and ethnicity [2]. Con-
sidering that fatigue is a core symptom of fibromyalgia [15], a
high prevalence of severe fatigue in patients with fibromyalgia
is an obvious expectation. However, evidence that severe fa-
tigue is higher in patients with a rheumatic disease and comor-
bid fibromyalgia is mixed [16–18].
The main objective of the current study was to provide an
overview of the prevalence of severe fatigue across a broad
range of rheumatic diseases in a single large international
sample of patients using a uniform measure of fatigue and a
stringent cutoff criterion indicating a level of fatigue that is
comparable with fatigue in patients with chronic fatigue syn-
drome. A secondary objective was to examine in which sub-
groups of patients severe fatigue is more prevalent; subgroups
were defined by the presence of (comorbid) fibromyalgia or
multiple rheumatic diseases not including fibromyalgia, dis-
ease duration, and demographic variables.
Methods
Participants
The study population comprised 6120 patients with rheumatic
diseases from different countries who participated between
November 2009 and September 2011 in an online study that
examined invalidation (i.e., patients’ perception of responses
of others that are denying, lecturing, not supporting, and not
acknowledging the condition of the patient [19]). Allied re-
searchers from several European countries and the USA asked
patient associations for rheumatic diseases in Europe and
North and South America to put a recruitment notice with a
hyperlink to the online questionnaire on their websites. The
text of the recruitment notice was similar across languages and
included information about the aim and content of the study,
inclusion criteria, and duration of participation (about 20min).
Based on this information, people could decide to participate
while being able to stop at any time if they desired. Inclusion
criteria were a self-reported diagnosis of at least one rheumatic
disease, being 18 years or older, and speaking one of the
languages in which the online questionnaires were provided
(i.e., Dutch, English, French, German, Portuguese, or Span-
ish). The study was conducted according to the principles of
the Declaration of Helsinki [20] and approved by the medical
ethical review board of the UniversityMedical Center Utrecht.
Further details of the study have been described [19].
Materials
In the online study, participants were asked which rheumatic
diseases they had, the disease duration, and demographic char-
acteristics. Several questionnaires were included. Relevant for
the current study was that fatigue was measured with the Vi-
tality scale of the RAND version of the SF 36-item Health
Survey, the RAND(SF)-36 [21–23]. For the Vitality scale,
both the content and scoring is equal across versions. The
reliability and validity of this questionnaire have been tested
for all languages included in this study and are satisfactory in
both the general population and in patient samples [24–30].
The Vitality scale assesses a general level of fatigue in the last
4 weeks using four items (i.e., Did you feel full of life/have a
lot of energy/feel worn out/feel tired) scored on a 6-point
Likert scale (all/most/a good bit/some/a little/none of the
time). The final score range is 0–100 with lower scores
representing more fatigue. In our study, scores of 35 or lower
were considered to indicate severe fatigue. This cutoff score is
similar to the 10th percentile of the general population [31]. To
identify patients with chronic fatigue syndrome, this cutoff
score was found to have 90 % sensitivity (i.e., 90 % of people
with chronic fatigue syndrome according to established clas-
sification criteria were correctly identified as having chronic
fatigue syndrome using this cutoff score) and 81 % specificity
(i.e., 81 % of the people not having chronic fatigue syndrome
according to established classification criteria were correctly
identified as not having chronic fatigue syndrome using this
cutoff score) [32].
Statistical analysis
In descriptive analyses, the cutoff score of ≤35 was used to
evaluate the number of patients with severe fatigue for groups
of patients with a single rheumatic disease or multiple rheu-
matic diseases. Single rheumatic diseases were represented by
a minimum of 75 patients. Single rheumatic diseases repre-
sented by less than 75 patients were included in analyses as
one combined group, Ba single other rheumatic disease.^
Logistic regression analysis examined the prevalence of
severe fatigue in specific groups. Standard descriptive vari-
ables gender, age, number of years of education (≤14 and
>14), marital status (single or divorced/widowed, with Bbeing
in a relationship^ as the reference category), and language
(English, French, German, Portuguese, and Spanish, with
Dutch as the reference category) were available in the dataset
and included in the analysis. Of disease-related variables, dis-
ease duration and the presence of (comorbid) fibromyalgia
and multiple rheumatic diseases (not including fibromyalgia)
were included; (comorbid) fibromyalgia, which was our larg-
est subgroup and has fatigue as part of the preliminary diag-
nostic criteria [15], was the only rheumatic disease included.
In case of multiple rheumatic diseases, the longest disease
duration was selected. The variable disease duration was log
transformed to correct the positively skewed score
distribution.
For the logistic regression analysis, regression coefficients
(B), standard errors (SE), Wald statistics, logistic pseudo
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partial correlations (r, i.e., the explanatory value attributable to
a single independent variable after adjusting for all other in-
dependent variables), odds ratios, and goodness of fit of the
whole model (Nagelkerke’s R2) are reported. Significance
levels were set at p<0.05. Data were analyzed using SPSS 20.
Results
Characteristics of the study population
Table 1 shows the characteristics of the 6120 patients with
rheumatic diseases. Almost half of the patients reported a diag-
nosis of fibromyalgia (49 %). The most commonly reported
combinations of rheumatic diseases were fibromyalgia and os-
teoarthritis (n=511), fibromyalgia and osteoarthritis and anoth-
er rheumatic disease (n=203), osteoarthritis and other rheumat-
ic diseases not being fibromyalgia (n=228, of which 102 had
rheumatoid arthritis), and rheumatoid arthritis and other rheu-
matic diseases not being osteoarthritis or fibromyalgia (n=181).
In total, this study covered 30 rheumatic diseases.
Participants resided in various countries around the world.
The most common countries of residence per language were
as follows: Dutch speakers lived mostly in the Netherlands
(n=1613) and Belgium (n=236); English speakers in the
UK (n=450), the USA (n=104), and Canada (n=78); German
speakers in Germany (n=520); French speakers in France (n=
680) and Belgium (n=62); Spanish speakers in Spain (n=
811), Argentina (n=266), Mexico (n=132), and Chile (n=
54); and Portuguese speakers in Portugal (n=687).
Prevalence of severe fatigue
The prevalence of severe fatigue is shown in Fig. 1 for patients
with a single rheumatic disease and patients with multiple
rheumatic diseases with or without fibromyalgia. Severe fa-
tigue was present in 65 % of all patients, with percentages
from 41 to 57 % in patients with a single inflammatory rheu-
matic disease, around 80 % in patients with fibromyalgia, and
35 % in patients with osteoarthritis.
Associations with severe fatigue
The logistic regression analysis (Table 2) showed that having
fibromyalgia, having multiple rheumatic diseases without fi-
bromyalgia, and being a member of the sample that did not
speak Dutch increased patients’ chance of being severely fa-
tiguedwhile having a longer disease duration, being older, and
having more years of education decreased patients’ chance.
Gender and marital status were not significantly associated
with severe fatigue (ps≥0.19). According to the partial corre-
lation adjusted for the other variables, having fibromyalgia
had the strongest association with severe fatigue of all
included independent variables (r=0.23). For patients with
fibromyalgia, it was four times more likely to be severely
fatigued than for patients without fibromyalgia. Language
was another variable with a strong association with severe
fatigue; most notably, for French speakers, the chance of being
severely fatigued was almost six times higher than for Dutch
speakers. The logistic analysis showed that, overall, severe
Table 1 Characteristics of the 6120 patients with rheumatic diseases
Female sex, n (%) 5391 (88)
Age, mean±SD 47 ±12
Men 50 ±12
Women 46 ±12
Years of education, n (%)
≤14 years 2673 (44)
>14 years 2959 (48)
Unknown 488 (8)
Marital status, n (%)
Single 963 (16)
Married or in a steady relationship 4480 (73)









Disease duration, median, interquartile range 5 2–11
Rheumatic disease, n (%)a
Fibromyalgia 2993 (49)
Osteoarthritis 1249 (20)
Rheumatoid arthritis 1054 (17)
Systemic lupus erythematosus 804 (13)
Ankylosing spondylitis/Bechterew’s disease 621 (10)
Sjögren’s syndrome 567 (9)
Psoriatic arthritis 240 (4)
Scleroderma 147 (2)
Polymyalgia rheumatica 93 (2)
Ehlers-Danlos syndrome or hypermobility syndrome 85 (1)
Juvenile idiopathic arthritis 81 (1)
Gout or pseudogout 62 (1)
Mixed connective tissue disease 56 (1)
Tietze’s syndrome/costochondritis 54 (1)
Another rheumatic diseaseb 149 (2)
a Due to patients with more than one rheumatic disease, the sum of per-
centages mentioned per rheumatic disease exceeds 100 %
b The most mentioned diseases in the category Banother rheumatic
disease^ are osteoporosis (n=22), Behçet’s disease (n=21), Still’s disease
(n=21), sarcoidosis (n=18), undifferentiated spondyloarthropathy (n=
15), and dermatomyositis (n=11)
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fatigue was less likely in patients who spoke Dutch than in
patients with another language. Supplementary analyses
showed that 64 % of Dutch-speaking patients with fibromy-
algia were severely fatigued versus 85 to 91% of patients with
fibromyalgia in populations with another language. The fit of
the total model (Nagelkerke’s R2) was 0.23, leaving more than
75 % of severe fatigue unexplained.
Discussion
This study in 30 rheumatic diseases shows that severe fatigue
is a widespread and highly prevalent problem across rheumat-
ic diseases. Overall, one out of every two patients was severe-
ly fatigued. Severe fatigue was least common in patients with
osteoarthritis (35 %) and most common in patients with
Fig. 1 Prevalence of severe fatigue [RAND(SF)-Vitality score ≤35] in
patients with rheumatic diseases. Of the 6120 patients, 6034 had a SF-
Vitality score; the number of patients with a missing score ranged per
rheumatic disease group from 3 to 16. BA single other rheumatic disease^
included all diagnoses which did not reach the minimum of 75 patients to
represent a specific rheumatic population. Patients with multiple rheumat-
ic diseases were divided into a group with fibromyalgia and a group
without fibromyalgia as one of the diagnoses
Table 2 Logistic regression
model examining associations
with severe fatigue (RAND(SF)-
Vitality ≤35)
B (SE) Wald statistic ra Odds ratio
Fibromyalgia 1.35 (0.07) 368.16*** 0.23 3.86
Multiple rheumatic diseases without FMb 0.49 (0.11) 20.95*** 0.05 1.63
Disease durationc −0.27 (0.08) 11.60** 0.04 0.76
Genderd −0.12 (0.10) 1.69 0.00 0.88
Age −0.01 (0.003) 11.15** 0.04 0.99
Years of educatione −0.30 (0.07) 19.87*** 0.05 0.74
Marital statusf
Single −0.08 (0.09) 0.93 0.00 0.92
Separated/widowed 0.01 (0.11) 0.03 0.00 1.01
Languageg
English 1.12 (0.12) 88.44*** 0.11 3.08
French 1.81 (0.13) 208.62*** 0.17 6.11
German 0.94 (0.12) 65.64*** 0.09 2.57
Portuguese 0.34 (0.11) 10.46** 0.03 1.41
Spanish 0.74 (0.08) 78.35*** 0.10 2.09
*=p<0.05; **=p<0.01; ***=p<0.001; BVariance^ explained by the total model, Nagelkerke’s R2 =0.23
a r is the logistic pseudo partial correlation, i.e., the explanatory value attributable to a single independent variable
after taking into account all other independent variables
b Having multiple rheumatic diseases without fibromyalgia (FM): yes=1, no=0
cDisease duration is log transformed
dGender: male=1 and female=0
eYears of education: >14 years=1, ≤14 years=0
fMarital status: two dummy variables with Bin a relationship^ as reference category
g Language: five dummy variables with Dutch as reference category
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(comorbid) fibromyalgia (around 80 %). Patients’ odds of
being severely fatigued were higher when having fibromyal-
gia, multiple rheumatic diseases without fibromyalgia, a
shorter disease duration, a younger age, and less years of ed-
ucation; also language was related to fatigue.
Thorough research into the prevalence of severe fatigue in
rheumatic diseases would demand random sampling, certifi-
cation of the rheumatic disease by a medical specialist, and
identifying chronic fatigue using classification criteria next to
self-report scores as has been done in chronic fatigue syn-
drome [33]. This type of prevalence studies have not been
done yet. Previous studies examining fatigue across rheumatic
diseases all had their limitations. One study examined three
rheumatic diseases and, like most other studies [5–7, 10], used
a sample of patients recruited in one rheumatology clinic [13].
Another used a sample of the general population in which the
presence of a rheumatic disease was determined by self-
reported diagnosis and did not present a cutoff for fatigue or
prevalence per rheumatic disease [3]. Overall measures to as-
sess fatigue varied across rheumatic diseases and in defini-
tions of fatigue severity [5–7, 9, 10] which impeded insight
into the prevalence of severe fatigue in distinct rheumatic dis-
eases. A strength of our study is that a uniform measure and
cutoff were used to estimate the prevalence in distinct rheu-
matic diseases. In spite of the diversity of assessment and
sampling methods in all studies thus far, our prevalence esti-
mates are in agreement with previous studies examining the
prevalence of severe fatigue [7, 13, 34] and lower than studies
examining prevalence of less severe levels of fatigue in rheu-
matic diseases [6, 9, 35].
Although having (comorbid) fibromyalgia increased pa-
tients’ odds of being severely fatigued, this study also clearly
showed that severe fatigue is by no means exclusive to pa-
tients with (comorbid) fibromyalgia; around 50 % of patients
with other rheumatic diseases are also severely fatigued. In-
deed, fatigue has been recognized in recent years as a core
symptom and outcome measure not only in fibromyalgia but
also in rheumatoid arthritis, psoriatic arthritis, and ankylosing
spondylitis [2, 5, 9, 15]. Patient-focused group discussions
indicated that fatigue is overwhelming and different from nor-
mal tiredness, that it permeates every sphere of life, and that
the possibilities of self-management are variable and profes-
sional support is rare [2, 36]. The current study showed high
prevalence of severe fatigue across 30 rheumatic diseases and
different cultural backgrounds. This suggests that fatigue
should be considered a core symptom and outcome measure
in clinical trials and clinical practice for all rheumatic diseases,
without exception. Moreover, the finding emphasizes that the
development and evaluation of adequate management and
treatment of fatigue in rheumatic diseases is of utmost
importance.
The pathology of fatigue is largely unknown. The high
prevalence of fatigue in rheumatic diseases suggests that the
inflammatory process is a precipitating and possible maintain-
ing factor of fatigue. This interpretation is somewhat support-
ed by the observation of a lower prevalence of fatigue among
patients with osteoarthritis, but it is contradicted by the high
prevalence being observed in fibromyalgia. Moreover, associ-
ations of clinical and laboratory variables with fatigue are
mostly low or absent [1, 2]. With current knowledge, Bacute^
fatigue as a result of a disease flare-up is probably best
targeted by pharmacological interventions, while behavioral
means such as life-style adjustment, cognitive behavioral ther-
apy, (graded) physical exercise training, and sleep hygiene
interventions should be considered in the treatment of chronic
fatigue [1, 37, 38].
The study being international increased the probability that
the findings are generalizable to different countries and cul-
tures, but it also indicated some differences in the prevalence
of severe fatigue between people with a different language.
The presence of severe fatigue varied substantially across lan-
guages with French-speaking patients most often reporting
severe fatigue and Dutch-speaking patients least often. Similar
findings have been reported for functioning and wellbeing, as
measured with the RAND(SF)-36, both between countries
and between language regions, with Dutch speakers having
more favorable scores than people with another language and
French speakers scoring relatively poor [39, 40]. These differ-
ences do not seem to be due to measurement invariance [39,
41] but have been attributed to differences in access to and
quality of national health systems [42], differences in social
and economic opportunities within countries [43], and culture
[44].
The current study has some limitations. It was based on
self-reported diagnoses of rheumatic diseases without certifi-
cation by a medical specialist, which may have led to the
incorrect reporting of rheumatic diseases. Moreover, the re-
cruitment through the Internet may have led to a lower repre-
sentation of the older patient population and patients with a
low social economic status, and it surely led to an overrepre-
sentation of some patient groups (e.g., those with larger or
more active patient associations). Furthermore, partly due to
the overrepresentation of some patient groups such as fibro-
myalgia which are mostly female, men are underrepresented
in this study. Finally, predominantly Western European coun-
tries participated in this study. Thus, our results might not be a
fair reflection of the prevalence of severe fatigue in older, male
patients and patients from other than Western European
countries.
The use of a generic questionnaire to measure fatigue en-
abled us to measure the severity of fatigue in multiple dis-
eases, and using a unidimensional measure may perhaps have
reduced confounding by other states such as depressed mood
that may differ among diseases. In rheumatoid arthritis, fa-
tigue has been defined as multidimensional in nature, includ-
ing physical, emotional, and cognitive aspects of fatigue and
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the daily impact of living with fatigue [45], a definition which
can be useful in clinical assessment. As our goal was to give
an overview of the prevalence of severe fatigue, not its impact,
across a broad range of rheumatic diseases, we chose the Vi-
tality scale of the RAND(SF)-36 which also had the advantage
that the results are directly comparable to the level of fatigue in
the general population.
A strength of the study is that a stringent uniform cutoff
score was used, which has been shown sensitive to identify
patients with chronic fatigue syndrome in the general popula-
tion [32]. However, to assure that this cutoff indeed measures
a level of severe fatigue comparable to chronic fatigue syn-
drome, future studies should examine if it is sensitive to iden-
tify severe fatigue using classification criteria other than self-
report only [33] in patients with rheumatic diseases.
This study is the first to provide an overview of the pres-
ence of severe fatigue across 30 rheumatic diseases using a
large international dataset, a uniform way of recruitment, a
uniform measure to assess fatigue, and a verified [31, 32]
cutoff score for severe fatigue. It showed that more than
50 % of all patients with a rheumatic disease are severely
fatigued. Severe fatigue can have detrimental effects for the
patient, the near environment, and society at large. A better
understanding of fatigue is crucial. In rheumatology,
unraveling the underlying mechanisms of fatigue and devel-
oping optimal treatments should be top priorities in research
and clinical practice.
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